1
|
Cheng AQ, Liu Z, Zhao L, Zhou XM, Cui ZY, Qin R, Li JX, Wei XW, Xiao D, Wang C. [Effect evaluation of "Smoking cessation: Doctor first"program in China]. Zhonghua Yi Xue Za Zhi 2022; 102:94-99. [PMID: 35701086 DOI: 10.3760/cma.j.cn112137-20211119-02582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To evaluate the effect of "Smoking cessation: Doctor first" program on smoking medical staff. Methods: From December 2016 to September 2019, 1 747 smoking medical staff from 54 units of China Tobacco Cessation Alliance were enrolled into"Smoking cessation: Doctor first"program. Demographic characteristics, smoking characteristics, degree of tobacco dependence, willingness to quit smoking and other related factors were collected during the baseline survey. Multivariate logistic regression model was used to analyze the related factors of willingness to quit. The subjects were given intensive smoking cessation intervention from October 2017 to September 2019, including education on the hazards of smoking, methods of smoking cessation and giving smoking cessation drugs. After intervention, the subjects were investigated about their smoking cessation progress and the effect of the project was evaluated. Results: The subjects were (41±11) years old, 91.9% (1 609/1 747) were male and 62.2% (1 086/1 747) were daily smokers. The main reasons for smoking included the influence of friends [697 (39.9%)], the need for social entertainment [629 (36.0%)], the relief of mental stress [589 (33.7%)] and the refreshment [459 (26.3%)]. At baseline, 52.9% (885/1 672) and 43.2% (755/1 747) smokers had intention to quit smoking and had planned to quit within one year, respectively. Multivariate logistic regression model analysis showed that: low education level [OR (95%CI) of high school and junior high school and below were 2.42 (1.61, 3.63) and 1.57 (1.18, 2.11)], daily smoking [OR (95%CI): 1.38 (1.06, 1.78)], thinking quitting smoking is not important [OR (95%CI): 4.15 (3.33, 5.18)] and having no quitting experience [OR (95%CI): 3.21 (2.53, 4.05)] were associated with no intention to quit smoking. After intensive smoking cessation intervention, 81.0% (1 415/1 747) smokers started to quit and 36.6% (518/1 415) quit smoking with drugs, both higher than the baseline level (all P values<0.001). By the end of the program, 60.2% (852/1 415) of the medical staff had quit smoking successfully. Conclusion: "Smoking cessation: Doctor first"program can improve the willingness to quit and the proportion of using smoking cessation drugs of medical staff.
Collapse
Affiliation(s)
- A Q Cheng
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - Z Liu
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - L Zhao
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - X M Zhou
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - Z Y Cui
- Graduate School of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing 100730, China
| | - R Qin
- Graduate School of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing 100730, China
| | - J X Li
- China-Japan Friendship School of Clinical Medicine, Graduate School of Capital Medical University, Beijing 100029, China
| | - X W Wei
- China-Japan Friendship School of Clinical Medicine, Graduate School of Capital Medical University, Beijing 100029, China
| | - D Xiao
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| | - Chen Wang
- Department of Tobacco Control and Prevention of Respiratory Diseases, China-Japan Friendship Hospital/WHO Collaborating Center for Tobacco Cessation and Respiratory Diseases Prevention/National Center for Respiratory Medicine/National Clinical Research Center for Respiratory Diseases/Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Beijing 100029, China
| |
Collapse
|
2
|
Qiao J, Qin R, Feng ZZ, Wu JF. [Gastric-type extremely well-differentiated adenocarcinoma of the stomach with lymph node metastasis: report of a case]. Zhonghua Bing Li Xue Za Zhi 2021; 50:1401-1403. [PMID: 34865438 DOI: 10.3760/cma.j.cn112151-20210607-00417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- J Qiao
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| | - R Qin
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| | - Z Z Feng
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| | - J F Wu
- Department of Pathology, the Second Hospital of Anhui Medical University, Hefei 230601, China
| |
Collapse
|
3
|
Qin R, Shi SS, Niu CL, Li ZJ, Diao H, Zhang RY. [Esophageal submucosal gland duct adenoma: report of a case]. Zhonghua Bing Li Xue Za Zhi 2021; 50:820-822. [PMID: 34405625 DOI: 10.3760/cma.j.cn112151-20201109-00834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- R Qin
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - S S Shi
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - C L Niu
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - Z J Li
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - H Diao
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| | - R Y Zhang
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, Shandong Province, China
| |
Collapse
|
4
|
Qin R, Wang H, Yan A. Classification and QSAR models of leukotriene A4 hydrolase (LTA4H) inhibitors by machine learning methods. SAR QSAR Environ Res 2021; 32:411-431. [PMID: 33896285 DOI: 10.1080/1062936x.2021.1910862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 03/27/2021] [Indexed: 06/12/2023]
Abstract
Leukotriene A4 hydrolase (LTA4H) is an important anti-inflammatory target which can convert leukotriene A4 (LTA4) into pro-inflammatory substance leukotriene B4 (LTB4). In this paper, we built 18 classification models for 463 LTA4H inhibitors by using support vector machine (SVM), random forest (RF) and K-Nearest Neighbour (KNN). The best classification model (Model 2A) was built from RF and MACCS fingerprints. The prediction accuracy of 88.96% and the Matthews correlation coefficient (MCC) of 0.74 had been achieved on the test set. We also divided the 463 LTA4H inhibitors into six subsets using K-Means. We found that the highly active LTA4H inhibitors mostly contained diphenylmethane or diphenyl ether as the scaffold and pyridine or piperidine as the side chain. In addition, six quantitative structure-activity relationship (QSAR) models for 172 LTA4H inhibitors were built by multiple linear regression (MLR) and SVM. The best QSAR model (Model 6A) was built by using SVM and CORINA Symphony descriptors. The coefficients of determination of the training set and the test set were equal to 0.81 and 0.79, respectively. Classification and QSAR models could be used for subsequent virtual screening, and the obtained fragments that were important for highly active inhibitors would be helpful for designing new LTA4H inhibitors.
Collapse
Affiliation(s)
- R Qin
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, Beijing, P. R. China
| | - H Wang
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, Beijing, P. R. China
| | - A Yan
- State Key Laboratory of Chemical Resource Engineering Department of Pharmaceutical Engineering, Beijing University of Chemical Technology, Beijing, P. R. China
| |
Collapse
|
5
|
Wei M, Shi S, Xu J, Shen B, Mou Y, Qin R, Fang W, Chen R, Wang W, Shao C, Yu X. Simultaneous resection of pancreatic cancer and liver oligometastases after induction chemotherapy in stage IV patients: An open-label prospective randomized multicenter phase III trial (CSPAC-1). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
He SJ, Qin R, Wang W, Zhang RY. [Clinicopathological characteristics and research progress of neuroendocrine adenoma of the middle ear]. Zhonghua Bing Li Xue Za Zhi 2019; 48:749-752. [PMID: 31495105 DOI: 10.3760/cma.j.issn.0529-5807.2019.09.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S J He
- Clinical Medical College, Jining Medical University of Shandong, Jining 272000, China
| | - R Qin
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, China
| | - W Wang
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, China
| | - R Y Zhang
- Department of Pathology, Affiliated Hospital of Jining Medical University of Shandong, Jining 272029, China
| |
Collapse
|
7
|
Wang L, Dehm SM, Hillman DW, Sicotte H, Tan W, Gormley M, Bhargava V, Jimenez R, Xie F, Yin P, Qin S, Quevedo F, Costello BA, Pitot HC, Ho T, Bryce AH, Ye Z, Li Y, Eiken P, Vedell PT, Barman P, McMenomy BP, Atwell TD, Carlson RE, Ellingson M, Eckloff BW, Qin R, Ou F, Hart SN, Huang H, Jen J, Wieben ED, Kalari KR, Weinshilboum RM, Wang L, Kohli M. A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone. Ann Oncol 2019; 29:352-360. [PMID: 29069303 DOI: 10.1093/annonc/mdx689] [Citation(s) in RCA: 61] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
Background Genomic aberrations have been identified in metastatic castration-resistant prostate cancer (mCRPC), but molecular predictors of resistance to abiraterone acetate/prednisone (AA/P) treatment are not known. Patients and methods In a prospective clinical trial, mCRPC patients underwent whole-exome sequencing (n = 82) and RNA sequencing (n = 75) of metastatic biopsies before initiating AA/P with the objective of identifying genomic alterations associated with resistance to AA/P. Primary resistance was determined at 12 weeks of treatment using criteria for progression that included serum prostate-specific antigen measurement, bone and computerized tomography imaging and symptom assessments. Acquired resistance was determined using the end point of time to treatment change (TTTC), defined as time from enrollment until change in treatment from progressive disease. Associations of genomic and transcriptomic alterations with primary resistance were determined using logistic regression, Fisher's exact test, single and multivariate analyses. Cox regression models were utilized for determining association of genomic and transcriptomic alterations with TTTC. Results At 12 weeks, 32 patients in the cohort had progressed (nonresponders). Median study follow-up was 32.1 months by which time 58 patients had switched treatments due to progression. Median TTTC was 10.1 months (interquartile range: 4.4-24.1). Genes in the Wnt/β-catenin pathway were more frequently mutated and negative regulators of Wnt/β-catenin signaling were more frequently deleted or displayed reduced mRNA expression in nonresponders. Additionally, mRNA expression of cell cycle regulatory genes was increased in nonresponders. In multivariate models, increased cell cycle proliferation scores (≥ 50) were associated with shorter TTTC (hazard ratio = 2.11, 95% confidence interval: 1.17-3.80; P = 0.01). Conclusions Wnt/β-catenin pathway activation and increased cell cycle progression scores can serve as molecular markers for predicting resistance to AA/P therapy.
Collapse
Affiliation(s)
- L Wang
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
| | - S M Dehm
- Masonic Cancer Center, University of Minnesota, Minneapolis, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA; Department of Urology, University of Minnesota, Minneapolis, USA
| | - D W Hillman
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - H Sicotte
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - W Tan
- Department of Medicine, Mayo Clinic, Jacksonville, USA
| | - M Gormley
- Janssen Research and Development, Spring House, Philadelphia, USA
| | - V Bhargava
- Janssen Research and Development, Spring House, Philadelphia, USA
| | - R Jimenez
- Department of Pathology and Lab Medicine, Mayo Clinic, Rochester, USA
| | - F Xie
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - P Yin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - S Qin
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - F Quevedo
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - B A Costello
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - H C Pitot
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - T Ho
- Department of Medicine, Mayo Clinic, Scottsdale, USA
| | - A H Bryce
- Department of Medicine, Mayo Clinic, Scottsdale, USA
| | - Z Ye
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
| | - Y Li
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - P Eiken
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - P T Vedell
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - P Barman
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - B P McMenomy
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - T D Atwell
- Department of Radiology, Mayo Clinic, Rochester, USA
| | - R E Carlson
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - M Ellingson
- Medical Genetics, Mayo Clinic, Rochester, USA
| | - B W Eckloff
- Medical Genome Facility, Mayo Clinic, Rochester, USA
| | - R Qin
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - F Ou
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - S N Hart
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - H Huang
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, USA
| | - J Jen
- Medical Genome Facility, Mayo Clinic, Rochester, USA; Division of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, USA
| | - E D Wieben
- Medical Genome Facility, Mayo Clinic, Rochester, USA
| | - K R Kalari
- Division of Biomedical Statistics and Informatics, Department of Health Sciences, Rochester, USA
| | - R M Weinshilboum
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - L Wang
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA.
| | - M Kohli
- Department of Oncology, Mayo Clinic, Rochester, USA.
| |
Collapse
|
8
|
Huang D, Li ZS, Fan XS, Wu HM, Liu JP, Sun WY, Li SS, Hou YY, Nie X, Li J, Qin R, Guo LC, Xu JH, Zhang HZ, Sun MM, Guo QN, Yang YH, Liu YH, Qin Y, Zhang LJ, Li JH, Zhang ZH, Gao P, Li YJ, Sheng WQ. [HER2 status in gastric adenocarcinoma of Chinese: a multicenter study of 40 842 patients]. Zhonghua Bing Li Xue Za Zhi 2018; 47:822-826. [PMID: 30423604 DOI: 10.3760/cma.j.issn.0529-5807.2018.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigation HER2 status in gastric adenocarcinoma of Chinese and contributing factors to the HER2 expression. Methods: HER2 status of 40 842 gastric adenocarcinomas and clinical data were retrospectively collected from 23 hospitals dated from 2013 to 2016. The association between HER2 positivity and clinicopathologic features was analyzed. Results: Of the 40 842 patients the median age was 62 years, the male female ratio was 2.6∶1.0. The rate of HER2 positivity was 8.8% (3 577/40 842). HER2 expression was related to the tissue type, tumor location, Lauren classification and tumor differentiation (P values: 0.009, 0.001, <0.01 and <0.01, respectively). Different HER2 expression status was observed between primary and recurrent tumors in 7.6% (48/635) cases. The rates of HER2 positivity ranged from 2% to 10% among different institutions. The rates of HER2 FISH amplification were dramatically different among the 23 hospitals (0-100%) with an average rate of 10% (810/8 156) in patients with HER2 IHC 2+ . Conclusions: HER2 expression is associated with clinicopathologic characteristics. HER2 re-assessment of tumor tissue and use of in situ hybridization techniques increase HER2 positivity. The current retrospective study should reflect the HER2 status in gastric adenocarcinoma of Chinese patients.
Collapse
Affiliation(s)
- D Huang
- Department of Pathology, Cancer Hospital, Fudan University, Shanghai 200032, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Wu YJ, Qin R, He JM, Cao ZY, Dong LG, Yang B. [The influence of chemotherapy-induced leucopenia on the disease-free survival of gastric cancer patients after radical gastrectomy]. Zhonghua Yi Xue Za Zhi 2018; 98:1919-1922. [PMID: 29996282 DOI: 10.3760/cma.j.issn.0376-2491.2018.24.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the association between chemotherapy-induced leucopenia and patients' disease-free survival in gastric cancer patients who received radical gastrectomy. Methods: The clinical data of 273 gastric cancer patients who received radical gastrectomy and postoperative adjuvant chemotherapy between January, 2010 and December, 2015 in PLA 309(th) hospital was reviewed retrospectively. Results: A total of 195 (71.4%) patients experienced at least one time of leucopenia, while it was absent in the other 78 (28.6%) patients. The median disease-free survival of patients with or without leucopenia was 49.7 and 44.0 months respectively (P=0.009), leucopenia was an independent factor influencing patients' disease-free survival (HR=2.758, P=0.022), but there was no statistical difference between the disease-free survival of patients with different degrees and frequency of leucopenia (P=0.446, 0.123). Conclusion: Chemotherapy-induced leucopenia is a predictor of good prognosis for gastric cancer patients who receive radical gastrectomy.
Collapse
Affiliation(s)
- Y J Wu
- Department of General Surgery, PLA 309th Hospital, Beijing 100091, China
| | | | | | | | | | | |
Collapse
|
10
|
Stujanna E, Murakoshi N, Tajiri K, Qin R, Feng D, Yonebayashi S, Ogura Y, Kimura T, Xu D, Aonuma K. P5381Rev-erb receptor agonist improves cardiac function through modulating inflammatory processes in myocardial infarction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Dunnick C, Mounessa J, Chapman S, Braunberger T, Qin R, Lipoff J, Dellavalle R. 367 Patient and provider satisfaction with teledermatology: A systematic review. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
12
|
Zhang G, Zhu Y, Qin W, Yu L, Wu G, Ma S, Wang F, Qin R, Yang X, Tao K, Yue S, Zhao G, Yang Z, Yuan J, Dou K, Yuan J. Combined Kidney Transplantation and Splenic Fossa Auxiliary Heterotopic Liver Transplantation in a Highly Sensitized Recipient: A Case Report. Transplant Proc 2017; 48:3191-3196. [PMID: 27932179 DOI: 10.1016/j.transproceed.2016.09.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2016] [Revised: 08/23/2016] [Accepted: 09/01/2016] [Indexed: 12/20/2022]
Abstract
BACKGROUND Combined kidney and auxiliary orthotopic liver transplantation from the same donor is used to treat highly sensitized renal transplant recipients. Auxiliary liver can protect the transplanted kidney against hyperacute rejection. METHODS In the current case, combined kidney and splenic fossa auxiliary heterotopic liver transplantation was performed from the same donor for a highly sensitized recipient without preoperative preconditioning. No postoperative hyperacute rejection occurred. RESULTS Seven days after surgery, preexisting antibody levels rose and decreased after treatment; meanwhile, the function of transplanted kidney returned to normal. During 24 months of follow-up, the grafts showed good blood perfusion and functioned well. The levels of preexisting antibodies, donor-specific antibodies (DSA) and C1q-fixing human leukocyte antigen (C1q-HLA) antibodies, all decreased. CONCLUSIONS Combined kidney and splenic fossa auxiliary heterotopic liver transplantation can be used in renal transplantation for highly sensitized recipients.
Collapse
Affiliation(s)
- G Zhang
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - Y Zhu
- Department of Urology, Hanzhong Central Hospital, Shanxi, China
| | - W Qin
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - L Yu
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - G Wu
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - S Ma
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - F Wang
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - R Qin
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - X Yang
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - K Tao
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - S Yue
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - G Zhao
- Xijing Orthopedic Hospital of the Fourth Military Medical University, Shanxi, China
| | - Z Yang
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - J Yuan
- Department of Biochemistry, University of Washington, Seattle, Washington
| | - K Dou
- Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Shanxi, China
| | - J Yuan
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Shanxi, China.
| |
Collapse
|
13
|
Zhang LJ, Wen Y, Zhu J, Qin R, Xi K. P-199THE NUMBER OF RESECTED LYMPH NODES IS ASSOCIATED WITH THE LONG-TERM SURVIVAL OUTCOME IN PATIENTS WITH T2N0 NON-SMALL CELL LUNG CANCER. Interact Cardiovasc Thorac Surg 2016. [DOI: 10.1093/icvts/ivw260.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Wen YS, Huang C, Zhang X, Qin R, Lin P, Rong T, Zhang LJ. Impact of metabolic syndrome on the survival of Chinese patients with resectable esophageal squamous cell carcinoma. Dis Esophagus 2016; 29:607-13. [PMID: 26123618 DOI: 10.1111/dote.12376] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Metabolic syndrome (MetS) is associated with the risk of esophageal squamous cell carcinoma (ESCC). However, the impact of MetS on survival has not been evaluated. A retrospective review was performed on 596 consecutive Chinese patients with esophageal squamous cell carcinoma who received surgery between January 2005 and October 2007. The clinical data and pretreatment information related to MetS were reviewed. The impact of MetS on overall survival (OS) was estimated by Kaplan-Meier and Cox proportional hazards analyses. MetS was a significant and independent predictor for better survival in patients with resectable ESCC. The 3-year OS and 5-year OS for patients with and without MetS were 75.0% versus 57.8% and 65.1% versus 44.6%, respectively (P = 0.005 in the univariate analysis, P = 0.010 in multivariate analysis). However, there was no apparent influence of any single component of MetS on OS. The other independent prognostic factors identified in the univariate analysis included the following: gender, smoking status, alcohol use, the extent of radical surgical resection, T and N stage, and tumor differentiation. The results of the multivariate analysis included the extent of radical surgery resection, T and N stage, and tumor differentiation. MetS was also associated with greater tumor cell differentiation (P = 0.036). There was no association found between MetS status and postoperative complications. MetS is an independent prognostic factor for OS in patients with ESCC and is associated with better tumor cell differentiation.
Collapse
Affiliation(s)
- Y-S Wen
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - C Huang
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - X Zhang
- School of Medicine, University of Glasgow, Glasgow, UK
| | - R Qin
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - P Lin
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - T Rong
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| | - L-J Zhang
- Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.,State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China
| |
Collapse
|
15
|
Liu P, Zhao Y, Qin R, Mo S, Chen G, Gu L, Chevrier DM, Zhang P, Guo Q, Zang D, Wu B, Fu G, Zheng N. Photochemical route for synthesizing atomically dispersed palladium catalysts. Science 2016; 352:797-801. [DOI: 10.1126/science.aaf5251] [Citation(s) in RCA: 1199] [Impact Index Per Article: 149.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2016] [Accepted: 04/05/2016] [Indexed: 11/02/2022]
|
16
|
Jimenez R, Sicotte H, Barman P, Sinnwell J, Eiken P, Atwell T, McMenomy B, Tan W, Wu K, Bryce A, Ho T, Pitot H, Quevedo J, Costello B, Dronca R, Moynihan T, Wang L, Qin R, Carlson R, Kohli M. 2523 Feasibility analysis of pathology and genetic yield from a prospective trial of tissue biopsies in metastatic castrate resistant prostate cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31342-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
17
|
Kohli M, Tan W, Eiken P, McMenomy B, Atwell T, Carlson R, Campion M, Wang L, Costello B, Pitot H, Quevedo F, Ho T, Bryce A, Qin R, Paz-Fumagalli R, Moynihan T, Dronca R, Liu M. 2573 Impact of biopsy of metastases on circulating tumor cell (CTC) counts in castrate resistant prostate cancer (CRPC). Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31392-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
18
|
He JM, Pu YD, Wu YJ, Qin R, Zhang QJ, Sun YS, Zheng WW, Chen LP. Association between dietary intake of folate and MTHFR and MTR genotype with risk of breast cancer. Genet Mol Res 2014; 13:8925-31. [PMID: 25366783 DOI: 10.4238/2014.october.31.7] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We investigated the association between dietary intake of folate, vitamin B6, and the 5,10-methylenetetrahydrofolate reductase (MTHFR) genotype with breast cancer. A matched case-control study was conducted, and 413 patients with newly diagnosed and histologically confirmed breast cancer and 436 controls were recruited. Folate intake, vitamin B6, and vitamin B12 levels were calculated, and the MTHFR C677T and A1298C and MTR A2756G polymorphisms were analyzed by polymerase chain reaction-restriction fragment length polymorphism. Breast cancer cases were generally older, older at first live birth, and younger at menarche, had a higher body mass index, were smokers, had higher energy intake, and more first-degree relatives with breast cancer as well as more live births compared to controls. With respect to energy intake, we found that higher energy intake were more likely to increase the risk of breast cancer. The MTHFR 667TT genotype was associated with a moderately increased risk of breast cancer when compared with the CC genotype, and a significant odds ratio (OR; 95% confidence interval, CI) was found (OR = 1.70, 95%CI = 1.06-2.73). Individuals carrying T allele were associated with higher risk of breast cancer when compared with C allele (OR = 1.34, 95%CI = 1.06-1.70). We did not find a significant effect of the MTHFR A1298C and MTR A2756G on the risk of breast cancer. We did not find any association between folate intake and MTHFR C677T polymorphisms. In conclusion, we found that the MTHFR C667T polymorphism is associated with the risk of breast cancer, indicating that this genotype plays a role in breast cancer development.
Collapse
Affiliation(s)
- J M He
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Y D Pu
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Y J Wu
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - R Qin
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Q J Zhang
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - Y S Sun
- Department of General Surgery, Hospital of the Chinese People's Liberation Army, Beijing, China
| | - W W Zheng
- General Surgery Department, Xinxiang Medical College, Weihui, China
| | - L P Chen
- General Surgery Department, Xinxiang Medical College, Weihui, China
| |
Collapse
|
19
|
Xu T, Wang H, Yan Y, Qin R, Jiang Y, Lu Y, Li W, Xia C, Chen J. O10.08 * HIGH G-PROTEIN-COUPLED RECEPTORS 65 (GPR65) EXPRESSION PREDICTS A POORER SURGICAL OUTCOME OF GLIOBLASTOMA PATIENTS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou174.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Zhang L, Li G, He GC, Zhu LL, Qin R, Jing SL. Isolation, characterization, and cross-transferability of microsatellite markers from the whitebacked planthopper (Sogatella furcifera). Genet Mol Res 2014; 13:6248-52. [PMID: 25158251 DOI: 10.4238/2014.august.15.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The whitebacked planthopper Sogatella furcifera (Horváth) (Hemiptera: Delphacidae) is one of the most harmful pests of rice. In this study, 18 polymorphic microsatellite markers were developed from S. furcifera genomic libraries using the fast isolation by amplified fragment length polymorphism of sequences containing repeat protocols. Microsatellite polymorphism was investigated using 32 individuals from one natural population. These 18 simple sequence repeat markers showed a number of alleles that ranged from 3 to 15 and had observed and expected heterozygosities that ranged from 0.094 to 0.871 and from 0.148 to 0.924, respectively. The high cross-species transferability of these markers was evaluated in three other planthopper species: Nilaparvata lugens, N. muiri China, and N. bakeri (Muir). These microsatellite markers will provide powerful tools for population genetic and ecological studies of this pest and its related species in the future.
Collapse
Affiliation(s)
- L Zhang
- Engineering Research Center of Protection and Utilization for Biological Resources in Minority Regions, South-Central University for Nationalities, Wuhan, Hubei, P.R. China
| | - G Li
- Engineering Research Center of Protection and Utilization for Biological Resources in Minority Regions, South-Central University for Nationalities, Wuhan, Hubei, P.R. China
| | - G C He
- State Key Laboratory of Hybrid Rice, College of Life Science, Wuhan University, Wuhan Hubei, P.R, China
| | - L L Zhu
- State Key Laboratory of Hybrid Rice, College of Life Science, Wuhan University, Wuhan Hubei, P.R, China
| | - R Qin
- Engineering Research Center of Protection and Utilization for Biological Resources in Minority Regions, South-Central University for Nationalities, Wuhan, Hubei, P.R. China
| | - S L Jing
- State Key Laboratory of Hybrid Rice, College of Life Science, Wuhan University, Wuhan Hubei, P.R, China
| |
Collapse
|
21
|
Fang Y, Shen H, Cao Y, Li H, Qin R, Chen Q, Long L, Zhu XL, Xie CJ, Xu WL. Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells. Braz J Med Biol Res 2014; 47:60-9. [PMID: 24519092 PMCID: PMC3932974 DOI: 10.1590/1414-431x20133324] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2013] [Accepted: 10/15/2013] [Indexed: 12/13/2022] Open
Abstract
MicroRNAs (miRNAs) are small RNA molecules that modulate gene expression implicated in cancer, which play crucial roles in diverse biological processes, such as development, differentiation, apoptosis, and proliferation. The aim of this study was to investigate whether miR-30c mediated the resistance of breast cancer cells to the chemotherapeutic agent doxorubicin (ADR) by targeting tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ). miR-30c was downregulated in the doxorubicin-resistant human breast cancer cell lines MCF-7/ADR and MDA-MB-231/ADR compared with their parental MCF-7 and MDA-MB-231 cell lines, respectively. Furthermore, we observed that transfection of an miR-30c mimic significantly suppressed the ability of MCF-7/ADR to resist doxorubicin. Moreover, the anti-apoptotic gene YWHAZ was confirmed as a target of miR-30c by luciferase reporter assay, and further studies indicated that the mechanism for miR-30c on the sensitivity of breast cancer cells involved YWHAZ and its downstream p38 mitogen-activated protein kinase (p38MAPK) pathway. Together, our findings provided evidence that miR-30c was one of the important miRNAs in doxorubicin resistance by regulating YWHAZ in the breast cancer cell line MCF-7/ADR.
Collapse
Affiliation(s)
- Y Fang
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - H Shen
- Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - Y Cao
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - H Li
- Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - R Qin
- Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - Q Chen
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - L Long
- Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Oncology, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - X L Zhu
- Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - C J Xie
- Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The First Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| | - W L Xu
- Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, ZhenjiangJiangsu, China, Department of Central Laboratory, The Fourth Affiliated People's Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
| |
Collapse
|
22
|
Zhang P, Xiao H, Liu H, Qin R. Regulation of zinc transporter 3 and carbonic anhydrases 2 and 14 mRNA expression in the retina of rats affected by low dietary zinc. Genet Mol Res 2014; 13:963-71. [DOI: 10.4238/2014.february.19.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
23
|
Peng F, Jiang J, Yu Y, Tian R, Guo X, Li X, Shen M, Xu M, Zhu F, Shi C, Hu J, Wang M, Qin R. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis. Br J Cancer 2013; 109:3092-104. [PMID: 24169343 PMCID: PMC3859942 DOI: 10.1038/bjc.2013.655] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2013] [Revised: 09/05/2013] [Accepted: 10/01/2013] [Indexed: 12/31/2022] Open
Abstract
Background: The multidrug resistance and distant metastasis of cholangiocarcinoma result in high postoperative recurrence and low long-term survival rates. It has been demonstrated that the ectopic expression of miR-200 suppresses the multidrug resistance and metastasis of cancer. However, the expression and function of miR-200 in cholangiocarcinoma has not yet been described. Methods: In this study, we identified dysregulated microRNAs (miRNAs, miR) in cholangiocarcinoma tissue by microarray analysis, and subsequent real-time PCR and northern blot analyses validated the expression of candidate miR. We performed functional analyses and investigated the relationship between miR-200b/c expression and the properties of cholangiocarcinoma cells. A dual luciferase assay was applied to examine the effect of miRNAs on the 3′-UTR of target genes, and we demonstrated the function of the target gene by siRNA transfection identifying the downstream pathway via western blotting. Results: We found significantly downregulated expression of four miR-200 family members (miR-200a/b/c/429) and then confirmed that ectopic miR-200b/200c inhibits the migration and invasion of cholangiocarcinoma cells both in vitro and in vivo. We found that miR-200b/c influenced the tumourigenesis of cholangiocarcinoma cells including their tumour-initiating capacity, sphere formation, and drug resistance. We further found that miR-200b/c regulated migration and invasion capacities by directly targeting rho-kinase 2 and regulated tumorigenic properties by directly targeting SUZ12 (a subunit of a polycomb repressor complex). Conclusion: Our study shows that miR-200b/c has a critical role in the regulation of the tumorigenic and metastatic capacity of cholangiocarcinoma and reveals the probable underlying mechanisms.
Collapse
Affiliation(s)
- F Peng
- Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei 430030, China
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Qin R, Chen Z, Ding Y, Hao J, Hu J, Guo F. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 2013; 60:486-92. [PMID: 23790166 DOI: 10.4149/neo_2013_063] [Citation(s) in RCA: 132] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Cervical cancer remains an important public health problem worldwide. New and effective therapeutic strategies targeting cervical cancer are urgently needed. Long non-coding RNAs (lncRNAs) are newly identified regulators in tumorigenesis and tumor progression. To investigate the role of lncRNA MEG3 in the development of cervical cancer, we examined MEG3 expression in 18 pairs of cervical cancer and matched adjacent non-neoplastic tissues. Real-time quantitative RT-PCR (qRT-PCR) results showed high expression levels of MEG3 in non-neoplastic tissues, but markedly lower levels in cancer tissues. We further investigated whether the restoration of MEG3 expression might affect the proliferation of cervical carcinoma cells. Ectopic expression of MEG3 inhibited the proliferation of human cervical carcinoma cells HeLa and C-33A in vitro. On the other hand, knockdown of MEG3 promoted the growth of well-differentiated cervical carcinoma HCC94 cells. Further investigation into the mechanisms responsible for the growth inhibitory effects revealed that overexpression of MEG3 resulted in the induction of G2/M cell cycle arrest and apoptosis. These results identified an important role of MEG3 in the molecular etiology of cervical cancer and implicated the potential application of MEG3 in cervical cancer therapy.
Collapse
Affiliation(s)
- R Qin
- Department of Gynecology and Obstetrics, Xinxiang Medical University, Henan, China.
| | | | | | | | | | | |
Collapse
|
25
|
Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. Cancer Gene Ther 2012; 19:839-44. [PMID: 23037808 PMCID: PMC3499676 DOI: 10.1038/cgt.2012.68] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The sodium iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to prostate cancer. We have developed a prostate tumor specific conditionally replicating adenovirus (CRAd) that expresses hNIS (Ad5PB_RSV-NIS). For radiovirotherapy to be effective in humans, the radioiodine dose administered in the pre-clinical animal model should scale to the range of acceptable doses in humans. We performed 131I dose-response experiments aiming to determine the dose required in mice to achieve efficient radiovirotherapy. Efficacy was determined by measuring tumor growth and survival times. We observed that individual tumors display disparate growth rates which preclude averaging within a treatment modality indicating heterogeneity of growth rate. We further show that a statistic and stochastic approach must be used when comparing the effect of an anti-cancer therapy on a cohort of tumors. Radiovirotherapy improves therapeutic value over virotherapy alone by slowing the rate of tumor growth in a more substantial manner leading to an increase in survival time. We also show that the radioiodine doses needed to achieve this increase scaled well within the current doses used for treatment of thyroid cancer in humans.
Collapse
Affiliation(s)
- M A Trujillo
- Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | |
Collapse
|
26
|
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.18_suppl.cra9015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
CRA9015 Background: Hot flashes are a common symptom during the menopause transition or following breast cancer treatment that can negatively impact the quality of life for many women. Preliminary data have suggested that flaxseed, a rich source of dietary lignans, may be a potentially effective treatment for hot flashes. Methods: A phase III randomized, placebo controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes. Postmenopausal women were randomly assigned to a flaxseed bar (providing 410 mg of lignans) for 6 weeks vs a placebo bar. Participants completed daily prospective, self report hot flash diaries during the baseline week and then began eating one study bar per day for 6 weeks, while continuing to record their daily hot flashes. The intra-patient difference in hot flash activity between baseline and the last treatment week was the primary endpoint. Side effects of the bars were evaluated through self report and CTC assessment. Results: Between October and December 2009, 188 women were enrolled onto this trial. Mean hot flash scores were reduced by 4.9 units in the flaxseed group and 3.5 in the placebo group (p=0.29). In both groups, a little over a third of the women received a 50% reduction in their hot flash scores. Only one side effect was significantly different between groups, that being grade 1 pruritis, which was more common (7%) in the placebo group versus 1% in the flaxseed group. Both groups reported increased abdominal distension, flatulence, diarrhea and nausea. Adherence and ability to detect treatment assignment did not differ between groups. Conclusions: The results of this trial do not support the use of 410 mg of flaxseed lignans for the reduction of hot flashes. The gastrointestinal side effects seen in both groups were likely due to the fiber content in the flaxseed and placebo bars.
Collapse
Affiliation(s)
- S. Pruthi
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - R. Qin
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - S. A. Terstriep
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - H. Liu
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - T. R. C. Shah
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - K. F. Tucker
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - M. J. Bury
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - R. L. Carolla
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - P. D. Steen
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - J. Vuky
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| | - D. L. Barton
- Mayo Clinic, Rochester, MN; Sanford Medical Center Fargo, Fargo, ND; Ann Arbor, Saginaw, MI; Ann Arbor, Warren, MI; Wichita Community Clinical Oncology Program, Wichita, KS; Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI; Cancer Research for the Ozarks, Springfield, MO; Roger Maris Cancer Center, Fargo, ND; Virginia Mason Medical Center, Seattle, WV
| |
Collapse
|
27
|
Morgan R, Oza AM, Qin R, Laumann KM, Mackay H, Strevel EL, Welch S, Sullivan D, Wenham RM, Chen HX, Doyle LA, Gandara DR, Erlichman C. A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset—A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Maples WJ, Picus J, Erlichman C. Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4548] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Pruthi S, Qin R, Terstriep SA, Liu H, Loprinzi CL, Shah TRC, Tucker KF, Dakhil SR, Bury MJ, Carolla RL, Steen PD, Vuky J, Barton DL. The evaluation of flaxseed for hot flashes: Results of a randomized, controlled trial, NCCTG study N08C7. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.cra9015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Dueck AC, Sargent DJ, Novotny PJ, Decker PA, Nelson H, Qin R, Sloan JA. Calibrating clinically significant effects in survival and response endpoints in cancer clinical trials. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
31
|
Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot HC, Tan W, Erlichman C, Vaishampayan UN. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.259] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
259 Background: Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are produced by bladder cancer cell lines in vitro and expressed in human tumor tissues. Preclinical studies have also shown that bladder cancer cell lines express VEGF receptor 1 and 2 on their surface membrane. Pazopanib is a vascular endothelial receptor tyrosine kinase inhibitor with anti-angiogenesis and antitumor activity in several preclinical models. A two-stage phase II study was conducted to assess the activity and toxicity profile of pazopanib administered to patients with metastatic, urothelial carcinoma. Methods: Patients with one prior systemic therapy for recurrent, metastatic urothelial carcinoma were eligible. Patients received pazopanib at a dose of 800 mg orally daily for 4 week cycle. Results: Nineteen patients were enrolled. Median age was 66 years, with > 89% of patients presenting poorly differentiated bladder cancer. Adverse event data is available on 18 patients. No grade 4 or 5 events have been experienced. Nine patients have experienced 11 grade 3 adverse events of which 7 were deemed at least possibly related to treatment. Most common toxicities were anemia, thrombocytopenia, leucopenia and fatigue. For stage 1, none of the first 16 evaluable patients were deemed success (CR or PR) by the RECIST criteria during the first four 4-week cycles of treatment. Median progression- free survival was 1.9 months. This met the futility stopping rule of interim analysis, and therefore, the trial was recommended to be permanently closed. Correlative studies including measurement of VEGF levels in archived tissues and blood are pending. Conclusions: Pazopanib did not show activity in urothelial carcinoma patients. The role of anti-VEGF therapies in urothelial carcinoma may need further evaluation in rational combination strategies. [Table: see text]
Collapse
Affiliation(s)
- R. Pili
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - R. Qin
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - P. J. Flynn
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - J. Picus
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - M. Millward
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - W. M. Ho
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - H. C. Pitot
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - W. Tan
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - C. Erlichman
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| | - U. N. Vaishampayan
- Roswell Park Cancer Institute, Buffalo, NY; Mayo Clinic Rochester, Rochester, MN; Metro Minnesota, Minneapolis, MN; Washington University School of Medicine, St. Louis, MO; Sir Charles Gairdner Hospital, Nedlands, Australia; Prince of Wales Hospital, Shatin, Hong Kong; Mayo Clinic Jacksonville, Jacksonville, FL; Karmanos Cancer Institute, Wayne State University, Detroit, MI
| |
Collapse
|
32
|
Wang H, Ni L, Yu C, Shi L, Qin R. Utilizing spiral computerized tomography during the removal of a fractured endodontic instrument lying beyond the apical foramen. Int Endod J 2010; 43:1143-51. [PMID: 21039622 DOI: 10.1111/j.1365-2591.2010.01780.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM To present a case that used spiral computerized tomography (CT) to locate and successfully remove a fractured endodontic instrument lying beyond the apical foramen using a surgical approach. SUMMARY The fracture of an endodontic instrument beyond the apical foramen is rare. In this case report, after an attempt to remove a fractured instrument failed, a multi-slice spiral computerized tomography (MSCT) was used for diagnosis and treatment planning. The fractured segment was precisely located and found in the soft tissue and successfully removed by surgery. For the successful removal of a fractured endodontic instrument beyond the apical foramen, the following are necessary: (i) knowledge of the cause of fracture and how to plan treatment; (ii) determining the precise location of the fractured segment using CT; and 3) skilful operation. KEY LEARNING POINTS • Fractured endodontic instruments might lie within the soft tissue. • Computerized tomography is an effective diagnostic aid for localizing the precise position of fractured instruments.
Collapse
Affiliation(s)
- H Wang
- Department of Operative Dentistry and Endodontics Department of Oral Radiology Department of Oral and Maxillofacial Surgery School of Stomatology, Fourth Military Medical University, Xi'an, China
| | | | | | | | | |
Collapse
|
33
|
Wang D, Gao S, Qin R, Browne G. Lateral movement of soil fumigants 1,3-dichloropropene and chloropicrin from treated agricultural fields. J Environ Qual 2010; 39:1800-1806. [PMID: 21043285 DOI: 10.2134/jeq2009.0474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
The soil fumigants 1,3-dichloropropene (1,3-D) and chloropicrin (CP) are often used for controlling soil-borne plant pathogens and parasitic nematodes before reestablishing new vineyards and orchards. To evaluate crop safety and environmental risks with the replant fumigation, four field experiments were performed over 2 yr to examine 1,3-D and CP lateral movement away from the treated fields. Shank injection with or without a virtually impermeable film (V1F) was used in two vineyard fumigation experiments, and spot drip application without tarp cover was used in two orchard experiments. Results showed that 1,3-D and CP gases moved laterally to 6 m from the treated fields when the fumigants were applied by shank injection. The maximum 1,3-D or CP soil gas concentration at 6 m was approximately 10 ng cm(-3) when the fumigated plot was not cover with a tarp. With VIF, the measured maximum concentration increased to approximately 100 ng cm(-3). In the spot drip application, maximum 1,3-D and CP gas concentrations reached approximately 100 ng cm(-3) but at 1.5 m radial distance from the point of fumigant injection.
Collapse
Affiliation(s)
- D Wang
- USDA-ARS, Water Management Research Unit, San Joaquin Valley Agricultural Sciences Center, Parlier, CA 93648, USA.
| | | | | | | |
Collapse
|
34
|
Erlichman C, Menefee ME, Northfelt DW, Qin R, Reid JM, Oursler M, Marks R, Haluska P, Molina JR, Koch K. Phase I trial of dasatinib (D) and lapatinib (L). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Wolf SL, Qin R, Menon SP, Rowland KM, Kugler JW, Flynn PJ, Christian D, Satele D, Berenberg JL, Loprinzi CL. Evaluation of a urea/lactic acid-based topical keratolytic agent (ULABTKA) for prevention of capecitabine-induced hand and foot syndrome (HFS): NCCTG trial N05C5. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Jones JM, Qin R, Bardia A, Linquist B, Wolf SL, Loprinzi CL. Prochlorperazine and 5HT3 antagonists for the treatment of breakthrough chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Trujillo MA, Oneal MJ, McDonough S, Qin R, Morris JC. A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer. Gene Ther 2010; 17:1325-32. [PMID: 20428214 PMCID: PMC2914818 DOI: 10.1038/gt.2010.63] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The sodium iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to other types of cancer, we transferred and expressed the sodium-iodide symporter (NIS) gene into prostate, colon, and breast cancer cells using adenoviral vectors. To improve vector efficiency we have developed a conditionally replicating adenovirus (CRAd) in which the E1a gene is driven by the prostate specific promoter, Probasin and the cassette RSV promoter-human NIScDNA-bGH polyA replaces the E3 region (CRAd Ad5PB_RSV-NIS). In vitro infection of the prostate cancer cell line LnCaP resulted in virus replication, cytolysis, and release of infective viral particles. Conversely, the prostate cancer cell line PC-3 (androgen receptor negative) and the pancreatic cancer cell line Panc-1 were refractory to the viral cytopathic effect and did not support viral replication. Radioiodine uptake was readily measurable in LnCaP cells infected with Ad5PB_RSV-NIS 24 hours post-infection, confirming NIS expression. In vivo, LnCaP tumor xenografts in nude mice injected intratumorally with Ad5PB_RSV_NIS CRAd expressed NIS actively as evidenced by 99Tc uptake and imaging. Administration of therapeutic 131I after virus injection significantly increased survival probability in mice carrying xenografted LnCaP tumors compared to virotherapy alone. The data indicate that Ad5PB_RSV_NIS replication is stringently restricted to androgen positive prostate cancer cells and results in effective NIS expression and uptake of radioiodine. This construct may allow multimodal therapy, combining cytolytic virotherapy with radioiodine treatment, to be developed as a novel treatment for prostate cancer.
Collapse
Affiliation(s)
- M A Trujillo
- Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN 55905, USA
| | | | | | | | | |
Collapse
|
38
|
Wang D, Browne G, Gao S, Hanson B, Gerik J, Qin R, Tharayil N. Spot fumigation: fumigant gas dispersion and emission characteristics. Environ Sci Technol 2009; 43:5783-5789. [PMID: 19731677 DOI: 10.1021/es9015662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Reducing emissions of volatile organic compounds (VOCs) from fumigant pesticides is mandatory in California, especially in "nonattainment areas" like the San Joaquin Valley that do not meet federal air quality standards. A two-year field study was conducted to examine the feasibility of site-specific fumigant application only at future tree sites with dramatically reduced amounts of fumigant chemicals on an orchard basis. Soil gas distribution and atmospheric emission of 1,3-dichloropropene and chloropicrin were measured after applying InLine using subsurface drip irrigation. It was predicted that except in the surface 20 cm of soil, satisfactory pest control could be achieved within a 15 cm radius from the injection point. Also, at radial distances of 15-51 cm from the point of fumigant injection, effective nematode control may be achieved. Cumulative atmospheric emission of the fumigants was estimated to be 18-23% of the applied active ingredients in plots that had been cover cropped with Sudan grass and 2-6% in plots that had remained bare for several months before treatment. Considering the significantly small amount of fumigant used on an orchard basis, the spot drip fumigation may achieve a 10-fold reduction in atmospheric VOCs load from fumigant pesticides.
Collapse
Affiliation(s)
- D Wang
- USDA-ARS, Water Management Research Unit, San Joaquin Valley Agricultural Sciences Center, Parlier, California 93648, USA.
| | | | | | | | | | | | | |
Collapse
|
39
|
Wolf SL, Qin R, Barton DL, Sloan JA, Liu H, Aaronson NK, Satele DV, Green NB, Mattar BI, Loprinzi CL. Relationship of sensory symptoms and motor function in patients with chemotherapy-induced peripheral neuropathy (CIPN) utilizing the EORTC QLQ CIPN20: NCCTG study N06CA. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9587] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9587 Background: CIPN is characterized by adjectives not covered directly by most common measures of pain and functional limitations. Possible descriptors include numbness, tingling and shooting/burning pain. A prospective neuropathy treatment trial provided data to explore the relationship between self-reported aspects of this symptom. Methods: Baseline EORTC QLQ CIPN20 data and NCI CTCAE V3.0 (CTC)neuropathy grade (I-IV) were provided for all patients on trial. Spearman correlation coefficients and Kappa's coefficients of agreement were calculated between individual items and subscales of the CIPN20 as well as the CTC neuropathy scale. Simple regression models were applied to examine the association between the sensory symptoms and motor function in the fingers/hands (F/H). 200 patients provided 80% power to detect a correlation coefficient of 0.20 with a 5% Type I error. Results: A majority of patients reported “quite a bit” to “very much” numbness (57%) or tingling (62%) in F/H compared to “a little” or “not at all” (numbness (43%), tingling (38%)) by the CIPN20. In contrast, only 13% of the participants had grade III/IV neuropathy determined by the CTC scale. Fewer patients reported the higher two levels of CIPN20-measured shooting/burning pain in F/H (20% “quite a bit” to “very much”). Numbness and tingling were highly correlated (kappa=0.56), while neither were in high agreement with shooting/burning pain (kappa= 0.05 (tingling) and 0.14 (numbness)). The CIPN20 sensory and motor subscales were significantly associated with each other (p<.0001) but were not or only weakly associated with the CTC. Specifically, tingling, numbness, and shooting/burning pain were not associated with the CTC (R=0.16, 0.18 and 0 .11, respectively). Using the CIPN20, all three sensations; numbness, tingling and shooting or burning pain were strongly associated with motor function. Conclusions: The most common moderate to severe CIPN symptoms were numbness and tingling with shooting/burning pain being less common. Shooting/ burning pain appears to be a separate symptom experience from numbness and tingling. The CTC neuropathy grading scale appears to be less sensitive than the CIPN20 in picking up sensory symptoms. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- S. L. Wolf
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - R. Qin
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - D. L. Barton
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - J. A. Sloan
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - H. Liu
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - N. K. Aaronson
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - D. V. Satele
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - N. B. Green
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - B. I. Mattar
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| | - C. L. Loprinzi
- Mayo Clinic, Rochester, MN; Netherlands Cancer Institute, Amsterdam, Netherlands; Missouri Valley Cancer Consortium, Omaha, NE; Wichita Community Clinical Oncology Program, Wichita, KS
| |
Collapse
|
40
|
Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Picus J, Maples WJ, Erlichman C. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5039] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5039 Background: Combined mTOR and VEGF blockade is a potentially promising and rational strategy for the treatment of advanced RCC. We previously reported the phase I safety and efficacy results of CCI 779 (C) +bevacizumab (B) n RTKI naïve stage IV RCC patients (pts) (J Clin Oncol. 2007;25[18S Suppl]:5034). We now report the interim results of the phase 2 study of C+B in RTKI refractory RCC patients. Methods: Design: Open label, phase I/II study of C+B in advanced RCC pts. Patients with measurable stage IV RCC with a component of clear/conventional cell type, performance status 0–2 and good organ function were eligible. Up to two prior treatment regimens were allowed (at least one prior RTKI). Phase II dose was C = 25 mg IV weekly and B = 10 mg/kg every 2 weeks repeated in 4 week cycles. The primary objective of the phase II portion was to assess the proportion of patients who were progression-free 6 months after study entry. Secondary objectives were assessment of response rates and toxicity. Accrual goal = 40 pts. Results: Thirty-five pts have been enrolled into the phase 2 portion to date with 4 pts ineligible. Twenty-five pts are evaluable for response assessment and 29 pts are evaluable for toxicity. Baseline characteristics (N: 35): M/F: 28/7; Number of met. sites: 1/2/3+: 15/9/11; prior nephrectomy: 31; Number of prior therapies: 1 = 29; 2 = 2. Most common (>5%) Gr 3–4 AEs (N = 29) included fatigue (6), hypercholesterolemia (2), hypertriglyceridemia (2), anorexia (2), rash (2), and anemia (2). Responses were: PR/SD/PD = 4 (16%)/18 (72%)/3 (12%). Median number of cycles administered was 4. Six month progression free rates will mature by may 2009. Conclusions: C+B combination at the recommended phase 2 doses is feasible and well tolerated. Clinical benefit rates (PR/SD) in RTKI refractory RCC patients (88%) are encouraging. Data on 6 month progression-free rates are expected to mature in 4/09. Updated data on safety, response rates, and 6-month progression free rates will be presented on all evaluable patients. Correlative studies on available plasma, serum and tumor samples for angiogenic and molecular biomarkers are underway. Supported by N01-CM62205, R21 CA 119545–02, and Commonwealth Foundation. [Table: see text]
Collapse
Affiliation(s)
- J. R. Merchan
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - H. C. Pitot
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - R. Qin
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - G. Liu
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - T. R. Fitch
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - J. Picus
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - W. J. Maples
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| | - C. Erlichman
- University of Miami School of Medicine, Miami, FL; Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI; Mayo Clinic, Scottsdale, AZ; Washington University, St Louis, MO; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Rochester, MN
| |
Collapse
|
41
|
Loprinzi CL, Qin R, Stella PJ, Rowland KM, Graham DL, Erwin N, Dakhil SR, Jurgens DJ, Burger KN. Pregabalin for hot flashes in women: NCCTG trial N07C1. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9513 Background: Hot flashes are a major problem in many women for which better treatment options are needed. Given the known efficacy of gabapentin for decreasing hot flashes, it was decided to evaluate pregabalin, with hopes that it would work better and/or with fewer toxicities. Methods: A three-arm, double-blinded, placebo-controlled randomized trial was developed. Women with bothersome hot flashes (at least 28/week) were randomized to receive either a placebo or target pregabalin oral doses of 75 mg bid or 150 mg bid (starting at 50 mg/d and then increasing the dose at weekly intervals to 50 mg bid, then 75 mg bid, and then, in the higher dose arm, 150 mg bid); patients were treated for 6 weeks. Hot flash numbers and scores (hot flash number times mean severity) were measured using a validated daily hot flash diary. A one-week baseline period preceded initiation of study tablets. The primary endpoint was the average intra-patient difference in hot flash score between baseline and week six, comparing the higher dose pregabalin arm and the placebo arm. With the planned sample size of 55 patients per arm, there was an 80% power and two-sided 5% Type I error rate to detect a difference of 0.54 standard deviations, or 1.08 hot flashes per day, or 2.7 units of hot flash score per day. Results: 207 patients were randomized between 6/20/2008 and 8/21/2008. The study arms were well balanced. Mean/median daily hot flash scores and frequencies for all pts at baseline were 15.7/13.4 and 8.3/7.7, respectively. The table shows the decreases in hot flashes from the baseline to the sixth treatment week. Larger numbers illustrate greater hot flash reductions. Toxicity information, quality of life information, and information regarding the effects of hot flashes on subjective symptoms will be available at the meeting time. Conclusions: Pregabalin reduces hot flashes in women. There appears to be similar effects with both studied doses. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. L. Loprinzi
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - R. Qin
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - P. J. Stella
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - K. M. Rowland
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - D. L. Graham
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - N. Erwin
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - S. R. Dakhil
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - D. J. Jurgens
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| | - K. N. Burger
- Mayo Clinic, Rochester, MN; St. Joseph Mercy Health System, Ann Arbor, MI; Carle Cancer Center, Urbana, IL; Carle Cancer Center, Urbana, IL; Illinois Cancer Care, Peoria, IL; Wichita Community Clinical Oncology Program, Wichita, KS; CentraCare Clinic, St. Cloud, MN
| |
Collapse
|
42
|
Barton DL, Wos E, Qin R, Mattar B, Green N, Lanier K, Bearden J, Kugler J, Rowland K, Loprinzi C. A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9531] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9531 Background: Chemotherapy induced peripheral neuropathy (CIPN) is a prevalent dose limiting toxicity for several important cancer treatment agents. CIPN can impair function and cause distress. There are no proven pharmacologic treatments for established CIPN currently. This double blind randomized placebo controlled trial evaluated a compounded topical gel for this problem. The novelty of this treatment is that it might incorporate several agents with different mechanisms of action to provide relief locally without negative systemic effects. Methods: Patients with CIPN (rated ≥4 out of 10) for at least one month, related to previous and/or concurrent exposure to neurotoxic agents, were randomized to baclofen 10 mg, amitriptyline HCL 40 mg and ketamine 20 mg in a pluronic lecithin organogel (BAK-PLO) vs placebo (PLO) to determine its effect on numbness, tingling, pain, and motor function. Exclusion criteria included other causes and/or current treatment for peripheral neuropathy. The primary endpoint was the baseline adjusted sensory subscale of the EORTC QLQ-CIPN20, at 4 weeks. Results: Between February and May 2008, 208 patients were enrolled onto this trial. Four week data are shown in the table below, higher numbers being better. The percentage of patients that had improvements of at least 10, on a 100 point scale, in the motor subscale was statistically significantly higher in the BAK-PLO arm, p=.04. There were no unwanted toxicities associated with the BAK-PLO that were significantly different from placebo and no evidence of CNS or systemic toxicity. Conclusions: Topical treatment with BAK-PLO appears to moderately improve symptoms of CIPN. This topical gel was well tolerated without systemic side effects. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. L. Barton
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - E. Wos
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - R. Qin
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - B. Mattar
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - N. Green
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - K. Lanier
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - J. Bearden
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - J. Kugler
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - K. Rowland
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| | - C. Loprinzi
- Mayo Clinic, Rochester, MN; Medcenter One Health System, Bismarck, ND; Mayo Clinic, Rochester, MN; Wichita Community Clinical Oncology Program, Wichita, KS; Missouri Valley Cancer Consortium CCOP, Omaha, NE; Providence Oncology and Hematology Care Clinic, Portland, OR; Gibbs Cancer Center, Spartanburg, SC; Illinois Cancer Care, Peoria, IL; Carle Cancer Center, Urbana, IL
| |
Collapse
|
43
|
Abstract
9628 Background: As multiple treatments have been studied for the management of hot flashes in randomized, controlled trials, hot flash placebo responses have been quite variable across trials. Based on observations of trial reports, it was hypothesized that the magnitude of placebo effect might correlate with the number of baseline hot flashes in different studies. The current project examines the effect of the baseline hot flash frequency required for study participation and also the actual number of baseline hot flashes observed as these individually relate to the eventual reductions of hot flash frequency observed in patients receiving placebos. Methods: Data were collected from placebo-controlled, double-blinded, randomized trials, identified by a PubMed search, which reported hot flash frequency at baseline, 4–6 weeks and 12 weeks. Trials were excluded if they had less than 20 participants completing the placebo arm. Data gathered, in each study, included the number of hot flashes required to enroll in the study, the average hot flash number during the baseline period, and the hot flash changes in the placebo arms of each study (percent reduction from the baseline period). A simple statistical analysis was conducted in a descriptive fashion since standard deviation was not available in many trials. Scatter plots and Pearson's correlation coefficients demonstrated the relationships between the placebo hot flash percent reduction from baseline and both the minimum required number of hot flashes at baseline, and the mean number of hot flashes at baseline. Results: 45 trials with 49 placebo arms were included in this analysis. A significant positive correlation was seen between the number of hot flashes required to enroll in a study and the percent reduction of hot flashes from baseline at 4–6 weeks (Rho = 0.481, p = 0.003). There was also a significant positive correlation between the number of hot flashes at baseline and the percent reduction of hot flashes from baseline at 4–6 weeks (Rho = 0.481, p= 0.002) and at 12 weeks (Rho = 0.573, p= 0.003). Conclusions: These data support that higher baseline hot flash enrollment requirements and also higher baseline hot flash frequencies are associated with an increased placebo response. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - R. Qin
- Mayo Clinic, Rochester, MN
| | | |
Collapse
|
44
|
Barton DL, Sloan JA, Loprinzi CL, Qin R. Response: Re: Randomized Controlled Trial to Evaluate Transdermal Testosterone in Female Cancer Survivors With Decreased Libido: North Central Cancer Treatment Group Protocol N02C3. J Natl Cancer Inst 2008. [DOI: 10.1093/jnci/djn312] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Kumar S, Marks RS, Richardson R, Quevedo F, Croghan GA, Markovic SN, Qin R, Tan AD, Molina JR, Erlichman CE, Adjei AA. A phase I study of the raf kinase/VEGF-R inhibitor sorafenib in combination with bortezomib in patients with advanced malignancy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2569] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Molina JR, Erlichman C, Kaufmann S, Adjei A, Rubin S, Friedman R, Reid J, Qin R, Felten S. A phase I study of lapatinib and topotecan in patients with solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3598] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3598 Background: Drug resistance to topotecan can be the result of BCRP/ABCG2 expression. BCRP is a member of the ABC transporter family that pumps anticancer drugs out of the cell. Lapatinib is a potent and selective dual inhibitor of epidermal growth factor receptor (EGFR or ErbB1) and ErbB2 (Her2/Neu). 4-aminoquinazoline tyrosine kinase inhibitors have been shown to enhance the cytotoxicity of topotecan through inhibition of BCRP-mediated drug efflux in cancer cells. Methods: Thirty-seven patients with advanced stage cancers were enrolled at escalating dose levels of lapatinib and topotecan in cohorts IA, IB and IIB (MTD). Treatment schedule included lapatinib (750 - 1500 mg/d) daily for 21 (cohort IA) or 28 days (cohort IB) and topotecan (2.4 - 4.0 mg/ m2), days 1, 8 and 15; cycles were repeated every 28 days. Three patients were treated at each dose level, 18 on cohort IA, 9 on cohort IB and 10 at MTD (cohort IIB). Assessments of toxicity were performed with each cycle and clinical response was determined per RECIST criteria every other cycle. Results: The MTD for cohorts IA and IB was reached at a dose of 1250 mg of lapatinib and 3.2 mg/m2 of IV topotecan on days 1, 8 and 15. No DLT were seen during the dose escalation stage of cohorts IA and IB. Ten patients were enrolled at the MTD. There were no grade 4+ events. Thirteen grade 3+ events, considered to be related to treatment, were seen in 6 patients. The most common grade 3+ toxicities included dehydration (2) diarrhea (2), nausea (3), vomiting (2), neutropenia (1), thrombocytopenia (1), and fatigue (1). No abnormalities in left ventricular ejection fraction were noted. Stable disease was seen in 46% of the 37 patients. Conclusions: The combination of lapatinib and topotecan is a well-tolerated regimen. The MTD for the combination is lapatinib 1,250 mg orally once daily for 21 or 28 days and topotecan 3.2 mg/m2 on days 1, 8 and 15. Pharmacokinetic analysis for drug interaction will be available for presentation at the meeting. Supported in part by GSK and Mayo Clinic No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. R. Molina
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - C. Erlichman
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - S. Kaufmann
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - A. Adjei
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - S. Rubin
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - R. Friedman
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - J. Reid
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - R. Qin
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| | - S. Felten
- Mayo Clinic, Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY; GlaxoSmithKline, Collegeville, PA
| |
Collapse
|
47
|
Merchan JR, Liu G, Fitch T, Picus J, Qin R, Pitot HC, Maples W, Erlichman C. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5034] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5034 Background: The mammalian target of rapamicin (mTOR) and vascular endothelial growth factor (VEGF) pathways are critically involved in the pathogenesis and progression of clear cell renal cell carcinoma. Methods: The goal of the phase I portion of the trial was to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of the combination of the mTOR inhibitor CCI-779 (C) and the anti-VEGF monoclonal antibody Bevacizumab (B). Patients with measurable stage IV clear cell RCC, performance status 0–2 and good organ function were eligible. Up to two prior treatment regimens were allowed. Treatment consisted of 25 mg IV weekly C and escalating IV doses of B (level 1= 5 mg/kg; level 2= 10 mg/kg) every other week. A cycle was defined as 4 weeks. Results: A total of 10 male and 2 female patients, median age 66 yrs (50–77) were enrolled to the phase I portion of the trial. PS: 0/1= 6/6; prior nephrectomy = 10; prior systemic therapy = 7 (prior cytokine therapy = 6); Number of metastatic sites: 1/2/≥3 = 2/2/8; one patient (out of 6) in dose level 1 experienced DLT which consisted of grade 3 hypertriglyceridemia. 1/6 patient in dose level 2 experienced DLT with grade 3 mucositis. Other grade 3 toxicities that were not DLTs included hypertension, proteinuria, hemorrhage, nausea/vomiting, dehydration, anorexia, pneumonitis, anemia, and hypophosphatemia. The best responses in the 12 evaluable patients included 7 PRs and 3 SDs. One patient had PD due to symptomatic deterioration and in one patient response information is not available at the time of this submission. Conclusions: Combination therapy with CCI-779 and Bevacizumab is safe and shows promising clinical antitumor activity. The recommended phase II dose is CCI-779 25 mg/week with bevacizumab 10 mg/kg every other week. The phase II study in stage IV renal cell cancer patients refractory to FDA approved receptor tyrosine kinase inhibitors is under way. The goals of the phase II portion are to determine the proportion of patients who have not had disease progression at 6 months, safety, response rates and correlative biomarker studies including determination of the tumor’s VHL-HIF-VEGF status, PTEN/AKT expression, plasma angiogenic activity and angiogenic cytokines. Supported by NCI N01-CM-62205 No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. R. Merchan
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - G. Liu
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - T. Fitch
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - J. Picus
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - R. Qin
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - H. C. Pitot
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - W. Maples
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| | - C. Erlichman
- University of Miami Miller School of Medicine, Miami, FL; University of Wisconsin, Madison, WI; Mayo College of Medicine, Scottsdale, AZ; Washington University School of Medicine, St Louis, MO; Mayo College of Medicine, Rochester, MN; Mayo College of Medicine, Jacksonville, FL
| |
Collapse
|
48
|
Qin R, Ahmed AS. The effect of ischemic re-perfusion injury plus particle infusion embolism on the apoptosis of rats with pancreatic cancer. Chin Med Sci J 2001; 16:204-8. [PMID: 12903756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
OBJECTIVES In an attempt to develop new method of treating the end- or mid-stage pancreatic cancer, we examined the effect of ischemic re-perfusion injury plus particle embolism on the pathology and cell apoptosis of pancreatic cancer in Sprague Dawely rats. METHODS 9 mg dimethylbeneanthracine (DMBA) were implanted directly into the parenchyma of pancreatic tail of Sprague-Dawely rats. After establishment of tumor, the inferior splenic artery, a main supplying vessel to pancreatic tail was subjected to blockade and re-opening for 30 min separately, then embolism particles were infused via the artery. Afterwards, artery was ligated. Pathological changes and cell apoptosis indicators (AI) of pancreatic cancer were observed by light microscopy and ISEL respectively 14 days after the operation. RESULTS The prevalence of pancreatic cancer among DMBA-implanted rats evaluated 3 months to 4 months after implantation was 59%. The volumes of the tumor in positive control group (B), pancreatic ischemic group (C), pancreatic ischemic re-perfusion injury group (D) were significantly larger than pancreatic ischemic re-perfusion injury plus particle thrombus group (E) ( P < 0.01). The volumes of the tumor in groups D, E were significantly smaller than that in group C (P < 0.01). There was a significant difference in tumor size between group B and group C ( P < 0. 01), but the difference was not significant between group D and group E ( P > 0.05). There was a significant infiltration of tumor tissue in group B rats, but strong inflammatory reaction was not noted. In groups C, D, E, a localized tumor growth was observed; infiltration of inflammatory cells and proliferation of fibroblasts and connective fiber were obvious, and some of these fibers grew into cancer nests and separate the tumor. The above findings were most conspicuous in group E. There was a significant difference in AI between group E (13.7 +/- 1.5) and other groups ( P < 0.01), with the difference being also significant between group C (4.3 +/- 2.4), D (8.5 +/- 1.1) and group B (1.2 +/- 0.8) (P < 0.01), and between group C and group D (P < 0.01) or between group D and group E ( P < 0.01). In the samples of group A, the apoptotic cells were not found. CONCLUSIONS Pancreatic ischemic re-perfusion injury plus particle thrombus can cause significant infiltration of inflammatory cells in tumor tissues thereby limiting its growth, and inducing cell apoptosis of pancreatic cancer. This effect is superior to either pancreatic ischemia alone or pancreatic ischemia plus re-perfusion injury.
Collapse
Affiliation(s)
- R Qin
- Department of Surgery, Tongji Hospital, Tongji Medical University, Wuhan 430030.
| | | |
Collapse
|
49
|
Zeng Q, Qin R, Zhang G, Qin C, Cao L, Chen Z. [Effects of radiofrequency catheter ablation in coagulation system]. Zhonghua Nei Ke Za Zhi 2001; 40:442-4. [PMID: 11798610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To investigate the pathogenesis and prophylactic therapy of peripheral vascular embolism after radiofrequency catheter ablation (RFCA). METHOD 90 patients with supraventricular tachycardia (SVT) were divided into 3 groups. Group A did not use any anticoagulant before RFCA and group B used aspirin (ASA) before RFCA, group C used calcium channel blocker-amlodipine before RFCA. Blood samples were taken at 4 time points, i.e. before and after electrophysiologic examination, immediately after RFCA and 2 days after RFCA. For each blood example, blood levels of platelet alpha-granule membrane glycoprotein-140 (Gmp-140), thromboxane B(2) (TXB(2)), protein C (PC), protein S (PS) were measured. RESULT In group A, Gmp-140 and TXB(2) of the blood examples taken before electrophysiologic examination were significantly lower than those taken at the three other time points, but there was no significant change of PC and PS as compared with that at the three other time points. Ablation either on the left or right heart did not affect the levels of Gmp-140 and TXB(2); In group B and group C, the levels of Gmp-140 and TXB(2) of the samples were significantly lower than those of the corresponding points in group A. CONCLUSION It is indicated that platelet aggregability may be introduced by RFCA, but evolution of the anticoagulant system was not caused by RFCA, This may enhance the occurrence of thrombosis. ASA and amlodipine may prevent the occurrence of thrombosis.
Collapse
Affiliation(s)
- Q Zeng
- Institute of Cardiovascular Disease, Xiehe Hospital, Tongji Medical University, Wuhan 430022, China
| | | | | | | | | | | |
Collapse
|
50
|
Lin W, Zhang N, Qin R. [Effect of aldose reductase expression by transforming growth factor-beta1 on rat mesangial cell]. Zhonghua Yi Xue Za Zhi 2001; 81:744-7. [PMID: 11798960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To screen the responsive genes related to transforming growth factor-beta1 (TGF-beta1) in rat mesangial cell (MsC) transfected by human TGF-beta1 gene, using suppression subtractive hybridization PCR (SSH-PCR); then to detect the expression of aldose reductase gene on cultured rat MsC and renal cortex of rats with anti-Thy1 glomerulonephritis. METHODS SSH-PCR technique and differential screening for detecting the responsive genes related to TGF-beta1; Semi-quantification RT-PCR and Western blot analysis for identifying the expression of aldose reductase on MsC in vitro and in vivo. RESULTS Compared with normal MsC, it was proved that 28 responsive genes related to TGF-beta1 in MTG1. There was an expression sequence tag (EST), approximate 337 bp segment, completely identical to the data of aldose reductase gene from GenBank. Elevated levels of aldose reductase mRNA and protein were found on cultured rat MsC treated with TGF-beta1 and renal cortex of rat with anti-Thy1 glomerulonephritis. CONCLUSION Aldose reductase, rate-limiting enzyme in the polyol pathway, was closely related to TGF-beta1 expression. It is possible that upregulation of aldose reductase expression may be involved in the development of glomerulosclerosis mediated by TGF-beta1.
Collapse
Affiliation(s)
- W Lin
- Department of Pathology, Medico Collegian Fudan University, Shanghai 200032, China
| | | | | |
Collapse
|